# Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients

> **NCT07703644** · — · NOT_YET_RECRUITING · sponsor: **Sizhou Feng** · enrollment: 60 (estimated)

## Conditions studied

- Hematologic Neoplasms
- Gram-Negative Bacterial Infections
- Pseudomonas Aeruginosa Infection
- Klebsiella Pneumoniae Infections
- Drug Resistance, Bacterial

## Interventions

- **DRUG:** Ceftazidime-avibactam
- **PROCEDURE:** Therapeutic Drug Monitoring (TDM) and Microbiological Surveillance

## Key facts

- **NCT ID:** NCT07703644
- **Lead sponsor:** Sizhou Feng
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-09
- **Primary completion:** 2027-07-09
- **Final completion:** 2027-07-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07703644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07703644, "Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07703644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*